JP2002524481A - 他の抗癌剤または理学療法と組み合わせたスクアラミンを使用する癌腫の処置 - Google Patents

他の抗癌剤または理学療法と組み合わせたスクアラミンを使用する癌腫の処置

Info

Publication number
JP2002524481A
JP2002524481A JP2000569761A JP2000569761A JP2002524481A JP 2002524481 A JP2002524481 A JP 2002524481A JP 2000569761 A JP2000569761 A JP 2000569761A JP 2000569761 A JP2000569761 A JP 2000569761A JP 2002524481 A JP2002524481 A JP 2002524481A
Authority
JP
Japan
Prior art keywords
tumor
treatment
squalamine
course
chemical compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000569761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002524481A5 (enExample
Inventor
ザスロフ，マイケル
ウィリアムズ，ジョン
ソコロフ，ミッチェル・エイチ
Original Assignee
ジェネーラ・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネーラ・コーポレーション filed Critical ジェネーラ・コーポレーション
Publication of JP2002524481A publication Critical patent/JP2002524481A/ja
Publication of JP2002524481A5 publication Critical patent/JP2002524481A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2000569761A 1998-09-10 1999-09-10 他の抗癌剤または理学療法と組み合わせたスクアラミンを使用する癌腫の処置 Pending JP2002524481A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15072498A 1998-09-10 1998-09-10
US09/150,724 1998-09-10
PCT/US1999/020645 WO2000015176A2 (en) 1998-09-10 1999-09-10 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities

Publications (2)

Publication Number Publication Date
JP2002524481A true JP2002524481A (ja) 2002-08-06
JP2002524481A5 JP2002524481A5 (enExample) 2006-10-26

Family

ID=22535747

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000569761A Pending JP2002524481A (ja) 1998-09-10 1999-09-10 他の抗癌剤または理学療法と組み合わせたスクアラミンを使用する癌腫の処置

Country Status (5)

Country Link
EP (1) EP1119361A4 (enExample)
JP (1) JP2002524481A (enExample)
AU (1) AU757649B2 (enExample)
CA (1) CA2343133A1 (enExample)
WO (1) WO2000015176A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040835A1 (en) * 1996-04-26 1997-11-06 Magainin Pharmaceuticals Inc. Treatment of carcinomas using squalamine in combination with other anti-cancer agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
JPS6133121A (ja) * 1984-07-25 1986-02-17 Nissei Marine Kogyo Kk 制癌剤
CA2157594A1 (en) * 1993-03-10 1994-09-15 Leah L. Frye Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
DE19606355A1 (de) * 1996-02-12 1997-08-14 Schering Ag Kontrazeptive Freisetzungssysteme mit antiviraler und/oder antibakterieller Wirkung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040835A1 (en) * 1996-04-26 1997-11-06 Magainin Pharmaceuticals Inc. Treatment of carcinomas using squalamine in combination with other anti-cancer agents

Also Published As

Publication number Publication date
EP1119361A2 (en) 2001-08-01
AU757649B2 (en) 2003-02-27
CA2343133A1 (en) 2000-03-23
WO2000015176A2 (en) 2000-03-23
WO2000015176A3 (en) 2000-07-20
EP1119361A4 (en) 2006-10-04
AU6496299A (en) 2000-04-03

Similar Documents

Publication Publication Date Title
US6596712B2 (en) Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
AU735884B2 (en) Treatment of carcinomas using squalamine in combination with other anti-cancer agents
RU2737496C2 (ru) Способы лечения рака
AU2015289504B2 (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
KR20160078987A (ko) 플리나불린 및 탁산의 조합에 의한 암 치료
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
Patel et al. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors
AU2005308539A1 (en) Method and composition for enhancing anti-angiogenic therapy
TWI891650B (zh) 治療血管畸形之方法
US11389536B2 (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
JP2023512724A (ja) リンパ腫の治療におけるピリド［１，２－ａ］ピリミジノン化合物の使用
US7018979B1 (en) Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
JP2002524481A (ja) 他の抗癌剤または理学療法と組み合わせたスクアラミンを使用する癌腫の処置
KR20250091332A (ko) 유비퀴틴-특이적 처리 프로테아제 1 (usp1) 억제제 및 parp1-선택적 억제제를 포함하는 치료적 조합물
JP2002524481A5 (enExample)
Ademuyiwa et al. Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer
Hsieh et al. Ctni-50. a Randomized Phase 2 Trial of Cediranib/Olaparib versus Bevacizumab in Patients with Recurrent glioblastoma: Updated Results
TW201130819A (en) Antitumor agent or postoperative adjuvant chemotherapeutic agent for treatment of hepatocellular carcinoma
WO2024102968A1 (en) Uses of ep2/ep4 antagonist compounds for treating familial adenomatous polyposis (fap)
Brandes et al. ACTR-78. TAMIGA: A PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF CONTINUOUS BEVACIZUMAB THROUGH MULTIPLE LINES OF TREATMENT FOR GLIOBLASTOMA
HK40026959A (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
Mogoş PHARMACOTHERAPY IN ADVANCED THYROID CANCER
WO2018069924A1 (en) Non-cytotoxic combination therapies and uses thereof in the treatment of cancer
HK40046839A (en) Androgen receptor modulator and uses thereof
HK1237267B (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20060908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100405